Patients receiving dapsone should be tested for glucose-6 phosphate dehydrogenase deficiency.
Inadequate data are available regarding efficacy or safety of atovaquone or clindamycin-primaquine.
TMP-SMZ reduces the frequency of some bacterial infections. Protection against Toxoplasma is provided by the preferred anti- Pneumocystis regimens. Pyrimethamine alone probably provides little, if any, protection. 5 years after the first dose is considered optional. These immunizations or chemoprophylactic regimens do not target pathogens traditionally classified as opportunistic but should be considered for use in HIV-infected patients.